Custom Search
Simvastatin News
FDA Approves VYTORIN (ezetimibe/simvastatin), the First and Only Product to Deliver Powerful LDL Cholesterol Reduction Through Dual Inhibition of the Two Sources of Cholesterol in One Tablet
VYTORIN(TM) lowered LDL cholesterol by 52 percent at the recommended starting dose (10/20 mg) and 60 percent at the maximum dose (10/80 mg).
New Study Showed VYTORIN(R) (ezetimibe/simvastatin) Superior to Lipitor in Reducing LDL ''Bad'' Cholesterol in Patients with Type II Diabetes at the Recommended Usual Starting Doses
Greater LDL Cholesterol Reduction with VYTORIN Compared to Lipitor Resulted in Greater LDL Cholesterol Goal Attainment
Two generics mean big savings
Health insurance companies tout use of generics as a way to control costs and reduce increases in co-payments and insurance premiums. Savings from just two major drugs — Zocor and Zoloft — that became available in generic form in...
Researchers' work from Poland, Germany and Denmark adds to statins body of knowledge
Statins data are the focus of recent research from Poland, Germany and Denmark.
AstraZeneca could gain as generic arrives
The introduction of a generic version of the blockbuster cholesterol drug Zocor this summer is not expected to take patients from AstraZeneca's own cholesterol reducer, Crestor.